Determining the appropriate regimen to use depends on many factors; such as, the character of the tumor, lymph node status, and the age and health of the patient.

This has been shown to reduce, though not completely prevent, the rate of infection and low white cell count.

Most adjuvant breast cancer chemotherapy regimens do not routinely require growth factor support except for those associated with a high incidence of bone marrow suppression and infection.

Assessment for CEP17, according to John Bartlett, professor of Molecular Pathology at the University of Edinburgh, could be easily carried out in the same FISH analysis as for HER2.

[13] For breast cancer, chemotherapy drugs are given into a vein (intravenously) or by mouth as tablets or capsules (orally).